Abstracts Archive - Page 2429 of 2607 - ACR Meeting Abstracts

Abstract Number: 2639 • 2012 ACR/ARHP Annual Meeting
Residual Disease Activity in Patients with Early Rheumatoid Arthritis Who Were Classified As Being in Remission According to 8 Different Descriptions: Post Hoc Analysis of the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: No single gold standard for remission is available for rheumatoid arthritis (RA). All available descriptions, including 2 proposed by an ACR/EULAR committee, allow residual…
Abstract Number: 2640 • 2012 ACR/ARHP Annual Meeting
Methotrexate Adverse Events in a Cohort of US Veterans with Rheumatoid Arthritis
Lisa A. Davis¹, Brooke Ivan Polk², Alyse D. Mann³, Gail S. Kerr⁴, Andreas M. Reimold⁵, Grant W. Cannon⁶, Ted R. Mikuls⁷ and Liron Caplan⁸, ¹Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, ²University of Colorado Medical School, Aurora, CO, ³Research, Denver VA Medical Center, Denver, CO, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁶Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Methotrexate (MTX) is the most commonly used medication for patients with rheumatoid arthritis (RA), however, the frequency of MTX adverse events (AE) has not…
Abstract Number: 2641 • 2012 ACR/ARHP Annual Meeting
Time-to-Improvement of Pain and Sleep in Clinical Trials of Pregabalin Treatment of Fibromyalgia
Lesley M. Arnold¹, Andrew Clair², Birol Emir², Lynne Pauer² and E. Malca Resnick², ¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, ²Pfizer Inc, New York, NY
Background/Purpose: Fibromyalgia (FM) is a chronic condition characterized by widespread pain and tenderness. Sleep disturbance is common in patients with FM, and both pain and…
Abstract Number: 2642 • 2012 ACR/ARHP Annual Meeting
Rate and Predictors of Work Disability in Fibromyalgia
Frederick Wolfe¹, Brian T. Walitt², Robert S. Katz³ and Winfried Häuser⁴, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Rheumatology, Washington Hospital Center, Washington, DC, ³Rush University Medical Center, Chicago, IL, ⁴Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany
Background/Purpose: Fibromyalgia is a contested disorder whose diagnosis depends largely on self-report. It is reportedly also associated with a high rate of work disability, but…
Abstract Number: 2643 • 2012 ACR/ARHP Annual Meeting
Grey Matter Decrease in Fibromyalgia Is Related to Pain Catastrophizing and Pain Sensitivity
Marta Ceko¹, Mary-Ann Fitzcharles², M. Catherine Bushnell¹ and Petra Schweinhardt¹, ¹McGill University, Montreal, QC, Canada, ²Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Fibromyalgia (FM) is commonly associated with catastrophizing, a set of negative emotional and cognitive processes related to pain. Catastrophizing is suggested to augment pain…
Abstract Number: 2644 • 2012 ACR/ARHP Annual Meeting
Functional Magnetic Resonance Imaging of Working Memory in Fibromyalgia: Support for a “Competing Demands” Theory of Cognitive Function in Chronic Pain
Anson E. Kairys¹, Gabriela Ramirez¹, Eric Ichesco², Johnson P. Hampson², Richard E. Harris², Daniel J. Clauw³, Tobias Schmidt-Wilcke² and Jennifer M. Glass⁴, ¹Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁴Psychiatry, University of Michigan, Ann Arbor, MI
Background/Purpose: The primary symptom of fibromyalgia (FM) is chronic widespread pain; however, patients report additional symptoms including decreased concentration and memory. Deficits are seen mainly…
Abstract Number: 2645 • 2012 ACR/ARHP Annual Meeting
The Transcription Factor Mohawk Plays an Important Role for Maintaining Human Anterior Cruciate Ligament Homeostasis
Hiroyuki Nakahara¹, Akihiko Hasegawa¹, Fumiaki Ayabe¹, Tetsuya Matsukawa¹, Koji Otabe¹, Tomo Yonezawa¹, Martin K. Lotz¹ and Hiroshi Asahara², ¹Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, ²Molecular & Experimental Med, The Scripps Research Institute, La Jolla, CA
Background/Purpose: Recently Mohawk homeobox (MKX) has been discovered as a tendon and ligament specific transcriptional factor. MKX deficient-mice are shown to hypoplastic tendons throughout the…
Abstract Number: 2606 • 2012 ACR/ARHP Annual Meeting
Patient Reported Outcomes in Early Arthritis Patients
L. Heimans¹, K.V.C. Wevers-de Boer¹, K. Visser¹, R. Goekoop², T.H.E. Molenaar³, B.A. Grillet⁴, Tom Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Haga Hospital, The Hague, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To investigate patient reported outcomes (PROs) of functioning and health related quality of life (HRQOL) after 1 year remission (DAS
Abstract Number: 2607 • 2012 ACR/ARHP Annual Meeting
Adherence to a Treat-to-Target Strategy in Early Rheumatoid Arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort
Marloes Vermeer¹, Ina H. Kuper², Hein J. Bernelot Moens³, Monique Hoekstra⁴, Marcel D. Posthumus⁵, Piet L.C.M. van Riel⁶ and Mart A.F.J. van de Laar⁷, ¹University of Twente & Medisch Spectrum Twente, Enschede, Netherlands, ²Medisch Spectrum Twente, Enschede, Netherlands, ³Ziekenhuisgroep Twente, Hengelo, Netherlands, ⁴Isala Klinieken, Zwolle, Netherlands, ⁵Department of Rheumatology, University of Groningen, University Medical Center, Groningen, Netherlands, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Rheumatology, University of Twente & Medisch Spectrum Twente, Enschede, Netherlands
Adherence to a Treat-to-Target Strategy in Early Rheumatoid Arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction CohortBackground/Purpose: A treat-to-target (T2T) approach has proven…
Abstract Number: 2608 • 2012 ACR/ARHP Annual Meeting
Time in Remission Is Important for Improvement of Physical Function in Patients with Rheumatoid Arthritis (RA)
Helga Radner¹, Farideh Alasti², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Physical function is one of the major outcomes in RA as it predicts work disability, quality of life, health care resource utilisation and mortality.…
Abstract Number: 2609 • 2012 ACR/ARHP Annual Meeting
Construct and Criterion Validity of Several Proposed DAS28 Based Rheumatoid Arthritis Flare Criteria: A Cohort Validation Study
Aatke van der Maas¹, Elisabeth Lie², Robin Christensen³, Ernest Choy⁴, Yaël A. de Man⁵, Piet L.C.M. van Riel⁶, Thasia G. Woodworth⁷ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Medicine, Division of Rheumatology, Visiting Clinical Researcher, Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: To enable consistent assessment of impact of tapering, withdrawal and dose optimization strategies, there is an increasing need for validated measures of flare in…
Abstract Number: 2610 • 2012 ACR/ARHP Annual Meeting
Predictors of Sustained Clinical Remissionin Early Rheumatoid Arthritis – Results From the Canadian Early Arthritis Cohort
Bindee Kuriya¹, Juan Xiong², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, Janet E. Pope⁶, J. Carter Thorne⁷, Diane Tin⁸, Edward Keystone⁹, Vivian P. Bykerk¹⁰ and CATCH¹¹, ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Dr. Vivian P. Bykerk, Toronto, ON, Canada
Background/Purpose: Rapid time-to-remission has been associated with sustained remission in established rheumatoid arthritis (RA)1. However, the prevalence and predictive factors of sustained remission in early…
Abstract Number: 2611 • 2012 ACR/ARHP Annual Meeting
Do Patients with Psoriatic Arthritis Fall Into Distinct Clinical Sub-Groups- a Cluster Analysis?
Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: To determine if demographic and disease characteristics of patients with PsA at presentation to a PsA clinic cluster into distinct groups. Methods: 1058 patients…
Abstract Number: 2612 • 2012 ACR/ARHP Annual Meeting
Localisation of Bone Marrow Edema in Sacroiliac Joints in Spondyloarthritis Patients: Does the Site of Lesions Change Over a 3-Month Period?
Manouk de Hooge¹, Rosaline van den Berg¹, Monique Reijnierse², Victoria Navarro-Compán¹, Floris van Gaalen¹, Tom Huizinga¹ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: A positive MRI at baseline is a strong predictor for a positive follow-up MRI1. But many questions about the volatility of the lesions over…
Abstract Number: 2613 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Anti-TNF Exposure: 24 Week Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Philip J. Mease¹, Roy Fleischmann², Jürgen Wollenhaupt³, Atul A. Deodhar⁴, Danuta Kielar⁵, Franz Woltering⁶, Christian Stach⁶, Bengt Hoepken⁶, Terri Arledge⁷ and Désirée van der Heijde⁸, ¹Seattle Rheumatology Associates, Seattle, WA, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³Schön-Klinik, Hamburg, Germany, ⁴Oregon Health & Science University, Portland, OR, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rheim, Germany, ⁷UCB Pharma, Rtp, NC, ⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, has shown efficacy in reducing signs and symptoms of psoriatic arthritis (PsA).1 RAPID-PsA (NCT01087788) is the first…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].